The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Blood Cancer Drugs-Global Market Insights and Sales Trends 2025
Synopsis
Blood cancers, or hematologic cancers, affect the production and function of blood cells. Most of these cancers start in the bone marrow where blood is produced.
The global Blood Cancer Drugs market size is expected to reach US$ 91940 million by 2029, growing at a CAGR of 5.5% from 2023 to 2029. The market is mainly driven by the significant applications of Blood Cancer Drugs in various end use industries. The expanding demands from the Leukemia, lymphoma and Multiple Myeloma,, are propelling Blood Cancer Drugs market. Blood Chemotherapy Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Blood Targeted Therapy Drugs segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Blood Cancer Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Blood Cancer Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Blood Cancer Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Blood Cancer Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Blood Cancer Drugs covered in this report include Amgen,, AstraZeneca PLC,, Astellas Pharma,, Bayer AG,, Bristol-Myers Squibb Company,, Celgene Corporation,, Eli Lilly,, F.Hoffmann-La Roche, and Johnson & Johnson,, etc.
The global Blood Cancer Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amgen,
AstraZeneca PLC,
Astellas Pharma,
Bayer AG,
Bristol-Myers Squibb Company,
Celgene Corporation,
Eli Lilly,
F.Hoffmann-La Roche,
Johnson & Johnson,
Novartis
Pfizer,
Takeda Pharmaceutical Company Ltd,
AbbVie
Global Blood Cancer Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Blood Cancer Drugs market, Segment by Type:
Blood Chemotherapy Drugs
Blood Targeted Therapy Drugs
Global Blood Cancer Drugs market, by Application
Leukemia
lymphoma
Multiple Myeloma
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Blood Cancer Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Blood cancers, or hematologic cancers, affect the production and function of blood cells. Most of these cancers start in the bone marrow where blood is produced.
The global Blood Cancer Drugs market size is expected to reach US$ 91940 million by 2029, growing at a CAGR of 5.5% from 2023 to 2029. The market is mainly driven by the significant applications of Blood Cancer Drugs in various end use industries. The expanding demands from the Leukemia, lymphoma and Multiple Myeloma,, are propelling Blood Cancer Drugs market. Blood Chemotherapy Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Blood Targeted Therapy Drugs segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Blood Cancer Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Blood Cancer Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Blood Cancer Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Blood Cancer Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Blood Cancer Drugs covered in this report include Amgen,, AstraZeneca PLC,, Astellas Pharma,, Bayer AG,, Bristol-Myers Squibb Company,, Celgene Corporation,, Eli Lilly,, F.Hoffmann-La Roche, and Johnson & Johnson,, etc.
The global Blood Cancer Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amgen,
AstraZeneca PLC,
Astellas Pharma,
Bayer AG,
Bristol-Myers Squibb Company,
Celgene Corporation,
Eli Lilly,
F.Hoffmann-La Roche,
Johnson & Johnson,
Novartis
Pfizer,
Takeda Pharmaceutical Company Ltd,
AbbVie
Global Blood Cancer Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Blood Cancer Drugs market, Segment by Type:
Blood Chemotherapy Drugs
Blood Targeted Therapy Drugs
Global Blood Cancer Drugs market, by Application
Leukemia
lymphoma
Multiple Myeloma
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Blood Cancer Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Blood Cancer Drugs
1.1 Blood Cancer Drugs Market Overview
1.1.1 Blood Cancer Drugs Product Scope
1.1.2 Blood Cancer Drugs Market Status and Outlook
1.2 Global Blood Cancer Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Blood Cancer Drugs Market Size by Region (2018-2029)
1.4 Global Blood Cancer Drugs Historic Market Size by Region (2018-2023)
1.5 Global Blood Cancer Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Blood Cancer Drugs Market Size (2018-2029)
1.6.1 North America Blood Cancer Drugs Market Size (2018-2029)
1.6.2 Europe Blood Cancer Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Blood Cancer Drugs Market Size (2018-2029)
1.6.4 Latin America Blood Cancer Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Blood Cancer Drugs Market Size (2018-2029)
2 Blood Cancer Drugs Market by Type
2.1 Introduction
2.1.1 Blood Chemotherapy Drugs
2.1.2 Blood Targeted Therapy Drugs
2.2 Global Blood Cancer Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Blood Cancer Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Blood Cancer Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Blood Cancer Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Blood Cancer Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Blood Cancer Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Blood Cancer Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Blood Cancer Drugs Revenue Breakdown by Type (2018-2029)
3 Blood Cancer Drugs Market Overview by Application
3.1 Introduction
3.1.1 Leukemia
3.1.2 lymphoma
3.1.3 Multiple Myeloma
3.2 Global Blood Cancer Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Blood Cancer Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Blood Cancer Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Blood Cancer Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Blood Cancer Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Blood Cancer Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Blood Cancer Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Blood Cancer Drugs Revenue Breakdown by Application (2018-2029)
4 Blood Cancer Drugs Competition Analysis by Players
4.1 Global Blood Cancer Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Blood Cancer Drugs as of 2022)
4.3 Date of Key Players Enter into Blood Cancer Drugs Market
4.4 Global Top Players Blood Cancer Drugs Headquarters and Area Served
4.5 Key Players Blood Cancer Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Blood Cancer Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Amgen,
5.1.1 Amgen, Profile
5.1.2 Amgen, Main Business
5.1.3 Amgen, Blood Cancer Drugs Products, Services and Solutions
5.1.4 Amgen, Blood Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Amgen, Recent Developments
5.2 AstraZeneca PLC,
5.2.1 AstraZeneca PLC, Profile
5.2.2 AstraZeneca PLC, Main Business
5.2.3 AstraZeneca PLC, Blood Cancer Drugs Products, Services and Solutions
5.2.4 AstraZeneca PLC, Blood Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 AstraZeneca PLC, Recent Developments
5.3 Astellas Pharma,
5.3.1 Astellas Pharma, Profile
5.3.2 Astellas Pharma, Main Business
5.3.3 Astellas Pharma, Blood Cancer Drugs Products, Services and Solutions
5.3.4 Astellas Pharma, Blood Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Bayer AG, Recent Developments
5.4 Bayer AG,
5.4.1 Bayer AG, Profile
5.4.2 Bayer AG, Main Business
5.4.3 Bayer AG, Blood Cancer Drugs Products, Services and Solutions
5.4.4 Bayer AG, Blood Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Bayer AG, Recent Developments
5.5 Bristol-Myers Squibb Company,
5.5.1 Bristol-Myers Squibb Company, Profile
5.5.2 Bristol-Myers Squibb Company, Main Business
5.5.3 Bristol-Myers Squibb Company, Blood Cancer Drugs Products, Services and Solutions
5.5.4 Bristol-Myers Squibb Company, Blood Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Bristol-Myers Squibb Company, Recent Developments
5.6 Celgene Corporation,
5.6.1 Celgene Corporation, Profile
5.6.2 Celgene Corporation, Main Business
5.6.3 Celgene Corporation, Blood Cancer Drugs Products, Services and Solutions
5.6.4 Celgene Corporation, Blood Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Celgene Corporation, Recent Developments
5.7 Eli Lilly,
5.7.1 Eli Lilly, Profile
5.7.2 Eli Lilly, Main Business
5.7.3 Eli Lilly, Blood Cancer Drugs Products, Services and Solutions
5.7.4 Eli Lilly, Blood Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Eli Lilly, Recent Developments
5.8 F.Hoffmann-La Roche,
5.8.1 F.Hoffmann-La Roche, Profile
5.8.2 F.Hoffmann-La Roche, Main Business
5.8.3 F.Hoffmann-La Roche, Blood Cancer Drugs Products, Services and Solutions
5.8.4 F.Hoffmann-La Roche, Blood Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 F.Hoffmann-La Roche, Recent Developments
5.9 Johnson & Johnson,
5.9.1 Johnson & Johnson, Profile
5.9.2 Johnson & Johnson, Main Business
5.9.3 Johnson & Johnson, Blood Cancer Drugs Products, Services and Solutions
5.9.4 Johnson & Johnson, Blood Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Johnson & Johnson, Recent Developments
5.10 Novartis
5.10.1 Novartis Profile
5.10.2 Novartis Main Business
5.10.3 Novartis Blood Cancer Drugs Products, Services and Solutions
5.10.4 Novartis Blood Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Novartis Recent Developments
5.11 Pfizer,
5.11.1 Pfizer, Profile
5.11.2 Pfizer, Main Business
5.11.3 Pfizer, Blood Cancer Drugs Products, Services and Solutions
5.11.4 Pfizer, Blood Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 Pfizer, Recent Developments
5.12 Takeda Pharmaceutical Company Ltd,
5.12.1 Takeda Pharmaceutical Company Ltd, Profile
5.12.2 Takeda Pharmaceutical Company Ltd, Main Business
5.12.3 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Products, Services and Solutions
5.12.4 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.12.5 Takeda Pharmaceutical Company Ltd, Recent Developments
5.13 AbbVie
5.13.1 AbbVie Profile
5.13.2 AbbVie Main Business
5.13.3 AbbVie Blood Cancer Drugs Products, Services and Solutions
5.13.4 AbbVie Blood Cancer Drugs Revenue (US$ Million) & (2018-2023)
5.13.5 AbbVie Recent Developments
6 North America
6.1 North America Blood Cancer Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Blood Cancer Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Blood Cancer Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Blood Cancer Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Blood Cancer Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Blood Cancer Drugs Market Dynamics
11.1 Blood Cancer Drugs Industry Trends
11.2 Blood Cancer Drugs Market Drivers
11.3 Blood Cancer Drugs Market Challenges
11.4 Blood Cancer Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
